General Information of Drug Combination (ID: DCY6JDX)

Drug Combination Name
Anamorelin ETHISTERONE
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Anamorelin   DM6HXTS ETHISTERONE   DMDXRP1
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.18
Bliss Independence Score: 4.18
Loewe Additivity Score: 16.71
LHighest Single Agent (HSA) Score: 16.71

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Anamorelin
Disease Entry ICD 11 Status REF
Carbohydrate metabolism disorder 5C51.Z Phase 3 [2]
Anamorelin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Growth hormone secretagogue receptor 1 (GHSR) TTWDC17 GHSR_HUMAN Stimulator [4]
Alpha-glucosidase (GLA) TTHCF4J LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of ETHISTERONE
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
ETHISTERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
ETHISTERONE Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Increases Expression [6]
Myb-related protein A (MYBL1) OTBJMC2P MYBA_HUMAN Increases Expression [6]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT01395914) Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3). U.S. National Institutes of Health.
3 TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-b... Bioorg Med Chem. 2007 Feb 1;15(3):1483-503.
4 Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
5 Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
6 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.